4
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Percutaneous management of hepatocellular carcinoma: Patient selection for percutaneous alcohol injection alone or combined with arterial chemoembolization

, , , , , , , & show all
Pages 65-70 | Published online: 10 Jul 2009
 

Summary

The purpose of our study was to assess the efficacy of percutaneous ethanol injection (PEI) alone or in combination with transarterial chemoembolization (TACE) for patients with hepatocellular carcinoma (HCC) not eligible for surgery. From January 1989 to December 1993, 46 patients (40 men, 6 women) with cirrhosis and histologically proven HCC were treated percutaneously. Twenty-six patients (56.5%) with single tumours smaller than 5 cm were treated with PEI alone. Twenty patients (43.5%) with multiple tumours or a single HCC 5cm or larger were treated with both PEI and TACE. Treatment results were evaluated by length of survival and findings on follow-up imaging studies. Survival rates in the group treated with PEI were 81% at 1 year, 70% at 2 years, and 56% at 3 years. In the group treated with PEI and TACE, survival was 79% at 1 year, 55% at 2 years, and 46% at 3 years. Treatment failed to control HCC in 16 patients (34.8%). There were no treatment-related major complications or deaths. As a means of palliative management, PEI is effective for solitary HCC smaller than 5cm, while PEI and TACE in combination are effective for larger or multiple turnours.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.